At a glance
ClinicalIndex Comparison RecordN/AActive· 27 enrolled
Drug / intervention
Mitral valve replacementdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Early Feasibility Study of the Neovasc Tiara™ Mitral Transcatheter Heart Valve With the Tiara™ Transapical Delivery System
In Brief
A clinical study evaluating Mitral valve replacement for Mitral Valve Regurgitation. Active but no longer recruiting, targeting 27 participants across 10 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and initial performance of the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMitral Valve Regurgitation
CountriesBelgium, Canada, United States
Collaborators--
Timeline
N/AActiveOverdue
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartDec 2014
Primary CompletionJan 2020
Study CompletionAug 2025
TodayJul 2026
First PostedOct 28, 2014
Enrollment StartDec 1, 2014
Primary CompletionJan 6, 2020
Study CompletionAug 1, 2025
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 11.7 years ago
Interventions
Mitral valve replacementdevice
Transcatheter mitral valve replacement